The Toll-like receptors (TLRs) are important for the innate immune system by recognizing pathogen-associated molecular patterns expressed in infectious agents. E6 and E7 protein from HPV16 suppress the host immune response by regulating the TLR9 transcript. Therefore, we hypothesized that a single nucleotide polymorphism in TLR9 may contribute to cervical cancer. We genotyped TLR9 -1486T/C (rs187084) in a case–control study of 712 cervical cancer cases and 717 cancer-free controls in Chinese women. Logistic regression analyses showed that the rs187084 heterozygote TC was associated with a significantly increased risk of cervical cancer (adjusted OR=1.28, 95% CI=1.01–1.62), compared with the TT genotype. Although the variant homozygote was associated with a nonsignificantly increased cervical cancer risk, the TC/CC genotypes contributed to the risk of cervical cancer in the dominant genetic model (adjusted OR=1.24, 95% CI=1.01–1.53). The findings indicate that TLR9 -1486T/C (rs187084) may contribute to cervical cancer carcinogenesis.
Get full access to this article
View all access options for this article.
References
1.
BeutlerB.2004. Inferences, questions and possibilities in Toll-like receptor signalling. Nature, 430:257–263.
2.
CampinoS., FortonJ., AuburnS., FryA., DiakiteM., RichardsonA.et al.2009. TLR9 polymorphisms in African populations: no association with severe malaria, but evidence of cis-variants acting on gene expression. Malar J, 8:44.
3.
ChenH.C., SchiffmanM., LinC.Y., PanM.H., YouS.L., ChuangL.C.et al.2011. Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst, 103:1387–1396.
4.
ChenX., HanS., WangS., ZhouX., ZhangM., DongJ.et al.2009. Interactions of IL-12A and IL-12B polymorphisms on the risk of cervical cancer in Chinese women. Clin Cancer Res, 15:400–405.
5.
ChuangT.H., UlevitchR.J.2000. Cloning and characterization of a sub-family of human toll-like receptors: hTLR7, hTLR8 and hTLR9. Eur Cytokine Netw, 11:372–378.
6.
FrazerI.H., LeippeD.M., DunnL.A., LiemA., TindleR.W., FernandoG.J.et al.1995. Immunological responses in human papillomavirus 16 E6/E7-transgenic mice to E7 protein correlate with the presence of skin disease. Cancer Res, 55:2635–2639.
HasanU.A., BatesE., TakeshitaF., BiliatoA., AccardiR., BouvardV.et al.2007. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol, 178:3186–3197.
9.
HurJ.W., ShinH.D., ParkB.L., KimL.H., KimS.Y., BaeS.C.2005. Association study of Toll-like receptor 9 gene polymorphism in Korean patients with systemic lupus erythematosus. Tissue Antigens, 65:266–270.
10.
ItoA., OtaM., KatsuyamaY., InokoH., OhnoS., MizukiN.2007. Lack of association of Toll-like receptor 9 gene polymorphism with Behcet's disease in Japanese patients. Tissue Antigens, 70:423–426.
11.
JaenO., Petit-TeixeiraE., KirstenH., AhnertP., SemeranoL., PierlotC.et al.2009. No evidence of major effects in several Toll-like receptor gene polymorphisms in rheumatoid arthritis. Arthritis Res Ther, 11:R5.
12.
LatzE., SchoenemeyerA., VisintinA., FitzgeraldK.A., MonksB.G., KnetterC.F.et al.2004. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol, 5:190–198.
13.
LazarusR., KlimeckiW.T., RabyB.A., VercelliD., PalmerL.J., KwiatkowskiD.J.et al.2003. Single-nucleotide polymorphisms in the Toll-like receptor 9 gene (TLR9): frequencies, pairwise linkage disequilibrium, and haplotypes in three U.S. ethnic groups and exploratory case-control disease association studies. Genomics, 81:85–91.
14.
LazarusR., VercelliD., PalmerL.J., KlimeckiW.J., SilvermanE.K., RichterB.et al.2002. Single nucleotide polymorphisms in innate immunity genes: abundant variation and potential role in complex human disease. Immunol Rev, 190:9–25.
15.
LiaoW., ChenR., LinH., LiuY., ChenW., TsaiY.et al.2010. Toll-like receptor gene polymorphisms are associated with susceptibility to Graves' ophthalmopathy in Taiwan males. BMC Med Genet, 11:154.
16.
MockenhauptF.P., CramerJ.P., HamannL., StegemannM.S., EckertJ., OhN.R.et al.2006. Toll-like receptor (TLR) polymorphisms in African children: Common TLR-4 variants predispose to severe malaria. Proc Natl Acad Sci USA, 103:177–182.
17.
MuradY.M., ClayT.M., LyerlyH.K., MorseM.A.2007. CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy. Expert Opin Biol Ther, 7:1257–1266.
18.
Nardelli-HaefligerD., LuratiF., WirthnerD., SpertiniF., SchillerJ.T., LowyD.R.et al.2005. Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. Vaccine, 23:3634–3641.
19.
NgM.W., LauC.S., ChanT.M., WongW.H., LauY.L.2005. Polymorphisms of the toll-like receptor 9 (TLR9) gene with systemic lupus erythematosus in Chinese. Rheumatology (Oxford), 44:1456–1457.
20.
ParkinD.M., BrayF., FerlayJ., PisaniP.2005. Global cancer statistics, 2002. CA Cancer J Clin, 55:74–108.
21.
RobinsonD.S., O'GarraA.2002. Further checkpoints in Th1 development. Immunity, 16:755–758.
22.
RozkovaD., NovotnaL., PytlikR., HochovaI., KozakT., BartunkovaJ.et al.2010. Toll-like receptors on B-CLL cells: expression and functional consequences of their stimulation. Int J Cancer, 126:1132–1143.
23.
TakedaK., KaishoT., AkiraS.2003. Toll-like receptors. Annu Rev Immunol, 21:335–376.
24.
TaoK., FujiiM., TsukumoS., MaekawaY., KishiharaK., KimotoY.et al.2007. Genetic variations of Toll-like receptor 9 predispose to systemic lupus erythematosus in Japanese population. Ann Rheum Dis, 66:905–909.
25.
TindleR.W.2002. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer, 2:59–65.
26.
WacholderS., ChanockS., Garcia-ClosasM., El GhormliL., RothmanN.2004. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst, 96:434–442.
